Constipation
📧 Sign up to get email alerts when something new happens for Constipation.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-28Clinical Trial Update: The Effect of Naldemedine on Opioid-induced Bowel Dysfunction [Phase 2]
Phase 2 clinical trial update evaluating naldemedine for opioid-induced bowel dysfunction and constipation.
-
CLINICAL_TRIALS trial_result · 2024-03-19Clinical Trial Update: Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety "Roll-over" Study (Rollover) [Phase 2]
A Phase 2 rollover safety study of ENT-01 for Parkinson's disease-related constipation was terminated, with results posted in 2024.
-
FDA approval · 2024-02-20FDA Approved: LACTULOSE SOLUTION — Supplemental Application (Bajaj Medical, LLC)
FDA approved Bajaj Medical, LLC's supplemental application for Lactulose Solution USP (10 g/15 mL), confirming continued availability of the…
-
CLINICAL_TRIALS trial_result · 2024-02-16Clinical Trial Update: Optimization of Transcutaneous Electrical Acustimulation (TEA) Modalities for Treatment of IBS-C [NA]
Completed clinical trial evaluating transcutaneous electrical acustimulation modalities for treating irritable bowel syndrome with constipat…
-
CLINICAL_TRIALS trial_result · 2023-12-04Clinical Trial Update: Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET) [Phase 2]
Phase 2 trial update for ENT-01 (oral) in Parkinson's disease-related constipation completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-11-30Clinical Trial Update: Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation [Phase 1, Phase 2]
Clinical trial updates on ENT-01 for Parkinson's Disease-related constipation report safety and tolerability data from Phase 1/2.
-
FDA approval · 2023-11-22FDA Approved: SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE ORAL — Original Application (Strides Pharma Science Limited)
FDA approved an original application for a generic oral combination of sodium sulfate, potassium sulfate and magnesium sulfate.
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: A Safety and Efficacy Evaluation of BLI801 Laxative in Adults Experiencing Non-Idiopathic Constipation [Phase 2, Phase 3]
Phase 2/Phase 3 clinical trial evaluating the safety and efficacy of BLI801 laxative for adults with non-idiopathic constipation has complet…
-
FDA label_change · 2023-09-18FDA Approved: MIRALAX — Supplemental Application (Bayer HealthCare LLC.)
The FDA approved a supplemental application for MIRALAX (polyethylene glycol 3350) by Bayer HealthCare LLC to update the labeling.
-
CLINICAL_TRIALS trial_result · 2023-09-18Clinical Trial Update: Long Term Efficacy of Sacral Nerve Modulation (SNM) in Patients With Constipation or Stool Incontinence
A completed clinical trial evaluating the long-term efficacy of sacral nerve modulation for constipation and fecal incontinence, with result…
-
FDA approval · 2023-08-29FDA Approved: CLENPIQ — Supplemental Application (Ferring Pharmaceuticals Inc.)
FDA approves a supplemental application for CLENPIQ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) submitted by Ferring Ph…
-
FDA approval · 2023-07-27FDA Approved: MIRALAX — Supplemental Application (Bayer HealthCare LLC.)
The FDA approved a supplemental application for Miralax (polyethylene glycol 3350) from Bayer HealthCare LLC.
-
CLINICAL_TRIALS trial_result · 2023-07-25Clinical Trial Update: Efficacy of Polyethylene Glycol vs Lactulose With Isabgol in Acute Fissure-in-Ano: PEGASIS Trial [Phase 2, Phase 3]
Clinical trial comparing polyethylene glycol to lactulose with isabgol for acute anal fissure, completed in Phase 2/3.
-
FDA approval · 2023-06-15FDA Approved: SUFLAVE — Original Application (Braintree Laboratories, Inc.)
The FDA approved SUFLAVE, an oral solution containing polyethylene glycol 3350 with electrolytes for bowel cleansing. This marks an original…
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of Goofice (Elobixibat) in patients with chronic constipation is ongoing or not ye…
-
CLINICAL_TRIALS trial_result · 2023-05-17Clinical Trial Update: Lcr35 for Children With Functional Constipation [NA]
Clinical trial completed for Lcr35 in children with functional constipation; results posted in 2023.
-
FDA approval · 2023-03-23FDA Approved: MIRALAX — Supplemental Application (Bayer HealthCare LLC.)
FDA approved a supplemental application for MIRALAX (polyethylene glycol 3350) by Bayer HealthCare LLC.
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section [Phase 4]
Phase 4 clinical trial update related to opioid-induced bowel dysfunction in cesarean section patients, focusing on constipation and postope…
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: Elobixibat for Chronic Constipation Without Defecation Desire [Phase 4]
Phase 4 trial update for elobixibat in chronic constipation without defecation desire has been terminated.
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids [Phase 4]
Phase 4 trial update on naloxegol to prevent opioid-induced constipation in critically ill adults; study terminated with posted results.
-
FDA approval · 2023-02-09FDA Approved: POLYETHYLENE GLYCOL 3350 NF — Supplemental Application (SUNRISE PHARMACEUTICAL, INC)
FDA approved a supplemental application for polyethylene glycol 3350 NF from Sunrise Pharmaceutical, Inc., indicating an approval-related up…
-
FDA approval · 2023-02-08FDA Approved: POLYETHYLENE GLYCOL 3350 — Supplemental Application (Major Pharmaceuticals)
FDA approved a supplemental application for polyethylene glycol 3350 from Major Pharmaceuticals, updating the product’s labeling/indication.…
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: Long-term Elobixibat for Chronic Constipation [Phase 4]
Phase 4 update on long-term elobixibat for chronic constipation.
-
FDA approval · 2022-12-07FDA Approved: POLYETHYLENE GLYCOL 3350 — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for polyethylene glycol 3350 from Aurobindo Pharma Limited, making this generic product available un…
-
FDA approval · 2022-11-02FDA Approved: POLYETHYLENE GLYCOL (3350) — Supplemental Application (Mylan Institutional Inc.)
The FDA approved a supplemental application for polyethylene glycol 3350 submitted by Mylan Institutional Inc.